| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Review |
Department of Bioimmunotherapy, University of Texas, M. D. Anderson Cancer Center, Houston, Texas
EBV was the first human virus to be directly implicated in carcinogenesis. It infects >90% of the world’s population. Although most humans coexist with the virus without serious sequelae, a small proportion will develop tumors. Normal host populations can have vastly different susceptibility to EBV-related tumors as demonstrated by geographical and immunological variations in the prevalence of these cancers. EBV has been implicated in the pathogenesis of Burkitt’s lymphoma, Hodgkin’s disease, non-Hodgkin’s lymphoma, nasopharyngeal carcinoma, and lymphomas, as well as leiomyosarcomas arising in immunocompromised individuals. The presence of this virus has also been associated with epithelial malignancies arising in the gastric region and the breast, although some of this work remains in dispute. EBV uses its viral proteins, the actions of which mimic several growth factors, transcription factors, and antiapoptotic factors, to usurp control of the cellular pathways that regulate diverse homeostatic cellular functions. Recent advances in antiviral therapeutics, application of monoclonal antibodies, and generation of EBV-specific CTLs are beginning to show promise in the treatment of EBV-related disorders.
This article has been cited by other articles:
|
|
 |
|
  A. Carbone, A. Gloghini, and G. Dotti EBV-Associated Lymphoproliferative Disorders: Classification and Treatment Oncologist, May 1, 2008; 13(5): 577 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-A. Xue and B. E. Griffin Complexities associated with expression of Epstein-Barr virus (EBV) lytic origins of DNA replication Nucleic Acids Res., May 11, 2007; 35(10): 3391 - 3406. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Dong, Y. Masaki, T. Takegami, T. Kawanami, K. Itoh, Z.-X. Jin, C.-R. Huang, X.-P. Tong, T. Fukushima, M. Tanaka, et al. Cloning and expression of two human recombinant monoclonal Fab fragments specific for EBV viral capsid antigen Int. Immunol., March 1, 2007; 19(3): 331 - 336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.-T. Liao, L.-B. Song, H.-Z. Zhang, X. Zhang, L. Zhang, W.-L. Liu, Y. Feng, B.-H. Guo, H.-Q. Mai, S.-M. Cao, et al. Centromere Protein H Is a Novel Prognostic Marker for Nasopharyngeal Carcinoma Progression and Overall Patient Survival Clin. Cancer Res., January 15, 2007; 13(2): 508 - 514. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J B Harley, I T W Harley, J M Guthridge, and J A James The curiously suspicious: a role for Epstein-Barr virus in lupus Lupus, November 1, 2006; 15(11): 768 - 777. [Abstract] [PDF]
|
|
|
|
 |
|
 A. N. Kirschner, J. Omerovic, B. Popov, R. Longnecker, and T. S. Jardetzky Soluble Epstein-Barr Virus Glycoproteins gH, gL, and gp42 Form a 1:1:1 Stable Complex That Acts Like Soluble gp42 in B-Cell Fusion but Not in Epithelial Cell Fusion J. Virol., October 1, 2006; 80(19): 9444 - 9454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Tai, M. Lin, F. Chang, G. Chen, F. Hsiao, N. Sutkowski, and B. T. Huber Murine Vbeta3+ and Vbeta7+ T Cell Subsets Are Specific Targets for the HERV-K18 Env Superantigen. J. Immunol., September 1, 2006; 177(5): 3178 - 3184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kaul, S. C. Verma, M. Murakami, K. Lan, T. Choudhuri, and E. S. Robertson Epstein-Barr Virus Protein Can Upregulate Cyclo-Oxygenase-2 Expression through Association with the Suppressor of Metastasis Nm23-H1 J. Virol., February 1, 2006; 80(3): 1321 - 1331. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Comoli, P. Pedrazzoli, R. Maccario, S. Basso, O. Carminati, M. Labirio, R. Schiavo, S. Secondino, C. Frasson, C. Perotti, et al. Cell Therapy of Stage IV Nasopharyngeal Carcinoma With Autologous Epstein-Barr Virus-Targeted Cytotoxic T Lymphocytes J. Clin. Oncol., December 10, 2005; 23(35): 8942 - 8949. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Batisse, E. Manet, J. Middeldorp, A. Sergeant, and H. Gruffat Epstein-Barr Virus mRNA Export Factor EB2 Is Essential for Intranuclear Capsid Assembly and Production of gp350 J. Virol., November 15, 2005; 79(22): 14102 - 14111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Moser, J. W. Upton, R. D. Allen III, C. B. Wilson, and S. H. Speck Role of B-Cell Proliferation in the Establishment of Gammaherpesvirus Latency J. Virol., August 1, 2005; 79(15): 9480 - 9491. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. O. Willer and S. H. Speck Establishment and Maintenance of Long-Term Murine Gammaherpesvirus 68 Latency in B Cells in the Absence of CD40 J. Virol., March 1, 2005; 79(5): 2891 - 2899. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
